Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy

Summary

This study is a phase I study of a new cell based prostate cancer therapy (ALECSAT). In this therapy specific cells from the patient's own immune system are isolated, activated and re-administered to the patient to boost a specific immune response against the cancer cells. The aim of the study is to show safety and tolerability for this type of therapy. It is the hypothesis that the cells administered during the therapy will attack the tumour cells and in this way stop or slow down the progression of disease.

Timeline

Start

2009-04

Primary completion

2010-07

Completion

2010-07

Publications

• Gammelgaard OL, Ehmsen S, Jylling AMB, Sandberg L, Kirkin AF, Kodahl AR, Ditzel HJ. Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with chemotherapy in locally advanced or metastatic triple-negative breast cancer: the ImmunoBreast phase Ib clinical trial. J Immunother Cancer. 2025 Dec 4;13(12):e012213. doi: 10.1136/jitc-2025-012213.

Drugs

Indications